Olanzapine/samidorphan

Olanzapine/samidorphan
Combination of
Olanzapine Atypical antipsychotic
Samidorphan Opioid modulator
Clinical data
Synonyms ALKS-3831
Legal status
Legal status

Olanzapine/samidorphan (developmental code name ALKS-3831) is a combination of the atypical antipsychotic olanzapine and the opioid modulator samidorphan which is under development by Alkermes, Plc. for the treatment of schizophrenia and bipolar mania.[1][2][3] As of June 2017, it is in phase III clinical trials for this indication.[1]

See also

References

  1. 1 2 http://adisinsight.springer.com/drugs/800037287
  2. ↑ Maric NP, Jovicic MJ, Mihaljevic M, Miljevic C (2016). "Improving Current Treatments for Schizophrenia". Drug Dev. Res. 77 (7): 357–367. doi:10.1002/ddr.21337. PMID 27633376.
  3. ↑ Fellner C (2017). "New Schizophrenia Treatments Address Unmet Clinical Needs". P T. 42 (2): 130–134. PMC 5265239. PMID 28163559.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.